[Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization].
[Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization].
复制标题
[肾细胞癌的肿瘤疫苗接种有或没有白介素 2 (IL-2) 作为佐剂。
DOI：
--
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
V. Schirrmacher
中科院分区：
文献类型：
--
作者：
S. Pomer;R. Thiele;G. Staehler;I. Drehmer;H. Löhrke;V. Schirrmacher
已知白细胞介素2（IL 2）的产生在产生抗肿瘤应答中绕过T辅助细胞功能。本分析旨在评估应用含和不含IL 2的肾癌疫苗对疫苗本身和肿瘤细胞攻击的迟发型超敏反应（DTH）皮肤反应的影响。肾癌疫苗由纽卡斯尔病病毒（NDV）感染的自体辐射肿瘤细胞和局部应用低剂量rIL 2（75，000个Cetus单位）组成。因此，补充rIL 2的共同管理被证明是重要的增强DTH反应肿瘤细胞的挑战。非整倍体肿瘤患者在未接种rIL 2的情况下，在整个接种过程中对疫苗无反应性。这种效应可以通过局部共同应用这种细胞因子来逆转。虽然使用基于IL 2的免疫治疗方案治疗肾癌患者似乎对晚期肾细胞癌有效，但应测试补充IL 2的疫苗以评估其在手术后“最小疾病”情况下的益处，特别是在具有非整倍体肿瘤的高风险患者中。
Interleukin 2 (IL2) production is known to bypass T-helper-cell function in the generation of an antitumour response. The present analysis was designed to assess the effects of application of renal cancer vaccine with and without IL2 on delayed-type hypersensitivity (DTH) skin responses to the vaccine itself and tumour cell challenge. The renal cancer vaccine consisted of Newcastle disease virus (NDV)-infected autologous irradiated tumour cells and topical application of low-dose rIL2 (75,000 Cetus units). As a result, the coadministration of a supplement of rIL2 proved to be important for augmentation of DTH responsiveness to tumour cell challenge. Patients with aneuploid tumours vaccinated without rIL2 developed an anergy to the vaccine throughout vaccination. This effect could be reversed by the topical coapplication of this cytokine. While the treatment of renal cancer patients with IL2-based immunotherapy regimens appears to be effective in advanced renal cell carcinoma the IL2-supplemented vaccines should be tested to assess their benefit in the situation of "minimal disease" after surgery especially in high-risk patients with aneuploid tumours.